Clinical trials: Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
The purpose of this study is to demonstrate if the use of Dermacyd can avoid the recurrence of bacterial vaginosis after three months of the standard treatment.
- Trial name
- NCT00556179
- Testing
- Lactoserum (Dermacyd Femina®)
- Where
- Brazil
- Volunteers
- 122 people
- Sponsor
- Sanofi
Bacterial Vaginosis
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
This research study is being done to evaluate the use of an oral (by mouth) medication called tinidazole to initially treat BV and then to see if additional treatment with tinidazole keeps women from getting this infection back…
- Trial name
- NCT00510614
- Testing
- tinidazole
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Pittsburgh
Recurrent Bacterial Vaginosis
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.
- Trial name
- NCT05033743
- Testing
- Secnidazole 2 GM Oral Granules
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Bacterial Vaginosis (BV), Recurrent Bacterial Vaginosis
Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.
This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.
- Trial name
- Vagitab (NCT06725888)
- Testing
- Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- S.I.I.T. Srl
Vulvovaginal Candidiasis
Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis
This single-center, randomized, single-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of oral Lactobacillus crispatus Lc-G22 as adjunctive therapy to clotrimazole for preventing recurrence of…
- Trial name
- NCT07727967
- Testing
- Lactobacillus crispatus Lc-G22
- Where
- China
- Volunteers
- 100 people
- Sponsor
- BioGrowing Co., Ltd
Bacterial Vaginosis, HIV
The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis
The proposed study, Hormonal Contraception \& BV (HCBV), will investigate the effect of NET-EN and DMPA on recurrent BV, vaginal microbiota and inflammatory markers among women at high risk for HIV in Kampala, Uganda.
- Trial name
- HCBV (NCT02905890)
- Testing
- Norethisterone enantate, Condoms
- Where
- Uganda
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Bacterial Vaginosis
Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
N-Acetyl cysteine (NAC) is an amino acid with strong antioxidant, mucolytic and antibacterial properties, and is produced within the human body.Its effect in biofilms has been tested in several bacteria.
- Trial name
- NCT01841411
- Testing
- N-Acetyl cysteine, Metronidazole + N-Acetyl cysteine, metronidazole
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Minia University
Recurrent Vulvovaginal Candidiasis
Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis
With the knowledge that VVC is an infectious disease of the genitourinary tract that is common in women of reproductive age, and because of the shortage of non-drug therapies for this condition, this study will aim to evaluate…
- Trial name
- NCT05795491
- Testing
- Blue Light Emitting Diode Therapy, Azole Antifungal
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Bacterial Vaginosis
Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome
The goal of this clinical trial is to learn about the vaginal microbiome in premenopausal women with recurrent bacterial vaginosis (BV).
- Trial name
- NCT05701722
- Testing
- Flourish HEC Vaginal Care System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vaginal Biome Science
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis
- Trial name
- NCT05074602
- Testing
- SHR8008, Fluconazole
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bacterial Vaginosis, Vaginal Flora Imbalance
Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis
Background Bacterial Vaginosis is the most common vaginal infection in women in their reproductive years and a difficult one to treat.
- Trial name
- NCT03734523
- Testing
- Flourish Vaginal Care System
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Vaginal Biome Science
Bacterial Vaginosis
Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence
Randomized controlled trial (RCT) to evaluate the effectiveness of applying Purell® (62% ethyl alcohol in emollient gel) to the penis of male partners of women diagnosed with BV for preventing BV recurrence after treatment.
- Trial name
- NCT00542074
- Testing
- hygienic information plus 62% ethyl alcohol in emollient gel, hygienic information
- Where
- Kenya
- Volunteers
- 223 people
- Sponsor
- University of Washington
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03562156)
- Testing
- Oteseconazole (VT-1161)
- Where
- 25 sites in United States
- Volunteers
- 438 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Candidiasis, Vulvovaginal
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during an acute episode and as prophylaxis, against recurrent…
- Trial name
- NCT05059145
- Testing
- Chlorhexidine Gluconate, Fluconazole
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Karolinska Institutet
Recurrent Bacterial Vaginosis
Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis
Recurrent bacterial vaginosis is a common condition in women of reproductive age and is characterized by a disruption of the normal vaginal microbiota, with a reduction in Lactobacillus species and an overgrowth of anaerobic…
- Trial name
- NCT07474831
- Testing
- Lactobacillus crispatus CRP21
- Where
- 11 sites in Italy
- Volunteers
- 132 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Candidiasis, Vulvovaginal, Yeast Infection
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
Non-interventional extension study to investigate VVC recurrence and candida colonization following the P2 acute VVC study
- Conditions
- Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal
- Trial name
- NCT02888197
- Where
- 23 sites in United States
- Volunteers
- 32 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginosis
A Study of the New Medical Device Polybactum®
The POLARIS trial is designed as a multicenter, open label, non-comparative, 3 months, clinical study. Interventional, non-controlled, multicenter trial with a prospective design on one cohort of patients
- Trial name
- POLARIS (NCT02863536)
- Testing
- Polybactum®
- Where
- Romania
- Volunteers
- 56 people
- Sponsor
- Effik Italia S.p.A.
Bacterial Vaginosis
LACTIN-V Study for Recurrent Bacterial Vaginosis
This Phase 2b trial is designed to provide a screening evaluation for the hypothesis that, following a 5-day treatment with MetroGel® to treat BV, L.
- Trial name
- NCT02766023
- Testing
- Lactobacillus crispatus CTV-05, Metronidazole
- Where
- 4 sites in United States
- Volunteers
- 228 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)